Supervisor: Dr Towhidkhah Designed by Yashar Sarbaz

Slides:



Advertisements
Similar presentations
Bear: Neuroscience: Exploring the Brain, 3e
Advertisements

Slide 1 Neuroscience: Exploring the Brain, 3rd Ed, Bear, Connors, and Paradiso Copyright © 2007 Lippincott Williams & Wilkins Bear: Neuroscience: Exploring.
Review: General Control Theory
Cortically OriginatedMovement Cortically Originated Movement I. Motor Tract (corticospinal tractus) Extrapyramidal System (basal ganglia) Cerebellum Praxis.
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
An Overview of Conventional and Experimental Treatments
Basal Ganglia and Motor Control L21
Basal Ganglia, Cerebellum and Movement
The Nervous System A network of billions of nerve cells linked together in a highly organized fashion to form the rapid control center of the body. Functions.
Movement part 2. Cerebellum and Brainstem KW p. 363.
Brain Control of Movement. Motor Control Hierarchy  High level – plans and executes strategy Association areas of cortex Basal ganglia gives the “go”
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
Neural Control of Muscle. Quick Review: Spinal Cord Flexors Extensors.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Assess Prof. Fawzia Al-Rouq Department of Physiology College of Medicine King Saud University Functional Anatomy of the Nervous System.
Dementia. Definition Loss of function in multiple cognitive abilities Assuming the individual had normal abilities before the onset Many of the 70 recognized.
Module 7.3 Movement Disorders. Parkinson’s Disease A neurological disorder characterized by muscle tremors, rigidity, slow movements and difficulty initiating.
CHAPTER V Movement disorders Part I: Anatomy and physiology of motor system.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Basal ganglia & cerebellar pathology
Pyramidal and extrapyramidal tracts
Parkinson’s Disease By Devin Cornford
Some Terminologies White matter : myelinated fibre tracts White matter : myelinated fibre tracts Gray matter : areas of neuronal cell bodies Gray matter.
Pooya Pakarian Presentation based on:
Making Things Happen - 2 Motor Disorders How Your Brain Works - Week 7 Dr. Jan Schnupp HowYourBrainWorks.net.
The Basal Ganglia. I.Functional anatomy A. Input and output components cerebral cortex  BG  thalamus (VA)  frontal lobe. B. Parallel circuits C. Neurotransmitters.
MODELING THE PARKINSONIAN TREMOR AND ITS TREATMENT Supervisor : Dr Towhidkhah Designed by Yashar Sarbaz Amirkabir University of Technology.
Parkinson’s Disease superKAT :).
Chapter Eight Movement
Neuroscience 1 Pause for thought: Probably 100 million neurones fire during skilled movements.
Brainstem and Basal Ganglia
Michael S. Beauchamp, Ph.D. Assistant Professor Department of Neurobiology and Anatomy University of Texas Health Science Center at Houston Houston, TX.
PhD MD MBBS Faculty of Medicine Al Maarefa Colleges of Science & Technology Faculty of Medicine Al Maarefa Colleges of Science & Technology Lecture – 9:
MOTOR AREAS EXTRAPYRAMIDAL SYSTEM
Sensorimotor systems Chapters 8.
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Clinical Approach to Neurologic Disorders Anatomic Pathophysiologic Phenomenologic Symptomatic Protective Curative Surgical.
BASAL GANGLIA Basal ganglia are subcorticle nuclei of grey matter located in the interior part of cerebrum near about base 3.
Brain Motor Control Lesson 20. Hierarchical Control of Movement n Association cortices & Basal Ganglia l strategy : goals & planning l based on integration.
Subcortical Motor Systems: Cerebellum & Basal Ganglia Lecture 21.
The Neurological Control of Movement
Basal Ganglia Principles of neural sciences 5 th ed. The human brain: an introduction to its functional anatomy 6 th ed. 林 永 煬 國立陽明大學 腦科學研究所.
Extrapyramidal pathway
PARKINSON’S DISEASE Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine.
Parkinson’s Test Device Development Tiffany Feltman Erin Sikkel.
Pathogenesis and pathology of parkinsonism
STRUCTURE AND CIRCUITS OF THE BASAL GANGLIA Rastislav Druga Inst. of Anatomy, 2nd Medical Faculty.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
Brain Mechanisms of Movement Lecture 19. Hierarchical Control of Movement n Association cortices & Basal Ganglia l strategy : goals & planning l based.
7 The Control of Action 1. Muscles, Motor Neurons and the Spinal Cord 2.
Direct motor pathway Corticospinal pathway. Motor Units – Large Versus Small Text Fig
Control of Posture and Movement- Part-IV Role of Basal Ganglia.
Direct motor pathway Corticospinal pathway.
Parkinson’s Disease.
Module 7.3 Movement Disorders
Department of Neuroscience
MOVEMENT DISORDERS.
Dr. Farah Nabil Abbas MBChB, MSc, PhD
Parkinson's disease KRZYSZTOF NICPOŃ.
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
Parkinson's disease Parkinson's disease (PD) is the second-most common
Basal ganglia function
MODELING THE PARKINSONIAN TREMOR AND ITS TREATMENT
Neurodegenerative diseases
Basal Ganglia April 28, 2019 basal ganglia.
Anatomy of the basal ganglia
Presentation transcript:

Supervisor: Dr Towhidkhah Designed by Yashar Sarbaz Amirkabir University of Technology BASAL GANGLIA Supervisor: Dr Towhidkhah Designed by Yashar Sarbaz

Systems-Level Neural Modelling: What and Why? We know a lot about the brain! Need to integrate data: molecular/ cellular/ systems levels. Complexity: Need to abstract away higher order principles Models are tools to develop explicit theories, constrained by multiple levels (neural and behavioural). Key: Models (should) make novel testable predictions on both neural & behavioural levels Models are useful tools for guiding experiments

Movement Levels Highest Level (Need & Plan): Limbic System Associative Cortex Middle Level (Motor Program): Cerebellum Motor Cortex Basal Ganglia Lowest Level (Movement): Spinal Cord Muscular-Skeletal System

Movement Block Diagram

Brain

Learning Strategies Supervised Learning (Cerebellum) Reinforcement Learning (Basal Ganglia) Unsupervised Learning (Cerebral Cortex) Symbolic Learning (Hippocampal System)

Learning Strategies

Learning Strategies Cerebral Cortex:Unsupervised Learning target error + - output input Cerebellum: Supervised Learning reward Basal Ganglia: Reinforcement Learning Cerebral Cortex:Unsupervised Learning Cortex Basal thalamus Ganglia SN Cerebellum IO

Basal Ganglia Collection of Subcortical Nuclui We Know a little about BG It has main role in movement Many movement disorders related to this area Involved in motor coordination, timing and control

Basal Ganglia Directly Receive No Direct Sensory Inputs Send Little Direct to Spinal Cord Damage in BG has no loss of Specific Motor Function Damage in BG Cause mainly Deficit in General Control and Initiation of Movement

Basal Ganglia It is one of the Old Area of Brain BG with Thalamus act like a Little Brain It is Like Funnel

BG Functions 1. Inhibition of muscle tone 2. Coordination of slow, sustained movements 3. Suppression of useless patterns of movements

Duty of the BG 1.Motor control 2.Reinforcement learning 3.Sensorymotor associative learning 4.Adaptive timing 5.Temporal order learning 6.Initiation of voluntary movement

BG is involved in a wide spectrum of functions ranging from simple sensory motor learning to planning, it does not tell to us how this might occur.

BG Blocks Striatum: Putamen and Caudate Globus Pallidus: External and Internal Subthalamic Nucleus Subtantia Nigra: Pars Compacta and Pars Reticulata

Basal Ganglia Anatomy

Basal Ganglia Anatomy

Basal Ganglia Anatomy

Basal Ganglia Anatomy

Blocks of BG

Converging Pathways PF: Prefrontal SMA: Supplementary Motor Area M1: Primary Motor Cortex PMv: Ventral pre-motor Area C/P: Caudate Nucleus

Disorders of the BG Hyperkinesia: an excess or spontaneous involuntary movements Chorea abrupt movements of the limbs and facial muscles Ballism violent, flailing movements Athetosis slow writhing movements of the fingers and hands and sometimes toes Hypokinesia: a lack of or resistance to voluntary movement Akinesia lack of of slowness of spontaneous and associative movements Rigidity increased tone on passive manipulation of joints Irregularities: Tremor rhythmic, involuntary, oscillatory movements around 4-6 Hz

BG Diseases Parkinson: loss of Dopamine, with hypokinesia (akinesia & rigidity) and irregulaities Huntington: death in striatum, with hyperkinesia (chorea, ballism, athrtosis) Hemiballism: lesion in STN with ballism Tardive Dyskinesia: Using Antipsychotic

BG Blocks in Diseases

BG and Action Selection BG selectively facilitates one command while suppressing others

Micro Circuitry of the BG Striosomes: input from limbic system and output to dopaminergic neuron of SNc (reinforcement signal) Matriosomes: Input from cortical (sensation and movement) and output to SNr and GP

Micro Circuitry of the BG

Conceptual Models Such diversity of function embodied in such an intricately organized structure, has inspired numerous models of basal ganglia function ranging from sensory-motor associative to the formation of motor plans

Conceptual Models BG as link between limbic system and motor output (eye movement)

Conceptual Models BG and learning to cortex to select a sequence

Reinforcement Learning

Physiological Basis of Reinforcement Learning

Physiological Basis of Reinforcement Learning

Reinforcement Learning A general idea of “goodness” is used to adjust how the system learns Temporal Difference (TD) error:

Reinforcement Learning Framework for learning state-action mapping (policy) by exploration and reward feedback Critic reward prediction Actor action selection Learning external reward r internal reward d: difference from prediction environment reward r action a state s agent

Dopamine and Learning There is significant evidence that dopamine acts as a reinforcement signal to neuron in striatum and training them to recognize patterns in their cerebral cortical input. Dopamine modulates Go and No-Go reinforcement learning in the basal ganglia separately via D1 and D2 receptors

Reinforcement Learning and BG Data from neuronal recording and lesion studies indicate that the basal ganglia are involved in learning and execution of goal-directed, sequential behaviour Dopamine neuron activity encoding the reward prediction error

Reinforcement Learning and BG It is suggested that the Striosome compartment works as the value prediction mechanism while the Matriosomes compartment works as the action selection mechanism

Reinforcement Learning and BG Striatum striosome & matrix dopamine-dependent plasticity Dopamine neurons reward-predictive response TD learning

Reinforcement Learning and BG

Striatum Learning Mechanism

Comparison of the Basal Ganglia and the Cerebellum The basal ganglia receive input from the entire cortex, whereas the cerebellum is innervated only by parts of cortex directly related to sensorimotor function Cerebellar output is directed back to the premotor and motor cortex, while the basal ganglia project to these as well as the prefrontal association cortex; The cerebellum receives somatosensory information directly from the spinal cord and has major afferents and efferents with many brain stem nuclei which are directly connected with the spinal cord, while the basal ganglia have very few connections with the brainstem and no known direct connections with the spinal cord

One might also consider that the basal ganglia are the deep nuclei of the cortex, while the cerebellum itself consists of a cerebellar cortex and deep nuclei.

History of Parkinson’s disease Ancient Indian Text: Kampavata Galen 175 A.D.: Shaking Palsy James Parkinson 1817: “An Essay on the Shaking Palsy” (6 patients) Charcot 1860: Parkinson’s Disease 1960: Role of Dopamine 1981: Levo Dopa 1990s: DBS Treatments

Parkinson’s Disease An Ancient Progressive Disease Second Wide-Spread Brain Disease (After Alzheimer) Main Symptoms are Movement Disorders Vast Range of Symptoms Mean Age of onset is 60 Degeneration of Basal Ganglia Not Epidemic

Famous Parkinsonian People

Etiology Not clear Exactly Main Hypothesis: Free Radicals: Antioxidant Molecules Genetic Factors Environmental Toxins: MPTP, Retenone, 6Hydroxy Dopamin SNc Cells Age Faster than Normal

Symptoms of PD Movement Symptoms Cognition Symptoms

Cognition Symptoms Dementia Depression Anxiety and Panic Sleep Disorders Cognitive impairment Psychosis Behavioural disturbances Bradyphrenia: off Thinking

Cognition Symptoms Different Movement and Cognition History Lewy Body Another Degeneration of Brain Area involve in Cognition (For Example in Dementia: Dorsal tier neuron and medial neuronal Groups) Aging

Movement Disorders Hypokinesia: a lack of or resistance to voluntary movement Akinesia: lack or slowness of spontaneous and associative movements Rigidity: increased tone on passive manipulation of joints Irregularities Tremor: rhythmic, involuntary, oscillatory movements around 4-6 Hz Gait Disturbance: shuffling gait, Freezing

Problems in Diagnosis Autopsy Show 24% Error in PD Diagnosis There is no Laboratory Test for Diagnosis 1. Patient History 2. Clinical tests 3. Using Levo dopa

Problems in Diagnosis Starting Tremor, Slowness and Stiffness approximately 12 month Before Diagnosis lesion of at least 50% of SNc Neuron Approximately Degeneration Start 5 year before Symptoms (10 years in some texts) Prognosis is important

Diagnosis of PD At Least Two of these Four Features (Cardinal Features): Tremor Rigidity Akinesia Gait disturbance Presence of rest tremor, and a clear cut response to treatment with levodopa

Physiological Information about PD Origin of PD (Basal ganglia) Parts of Basal ganglia (BG) Comparing Normal and Patient

Reason of PD Loss of nerve cells in substantia nigra pars compacta Low level of Dopamine in patient’s brain Changing activity of other blocks

Theory of PD Inhibition of GPi Theory BG Selective Theory Oscillatory Theory Complex Dynamic System Theory

BG Changes in PD [Kandel, 2000] Normal Person Parkinsonian Person

States of disease After unfolding movement Symptoms Before unfolding movement Symptoms

Treatments for PD Nonpharmacologic treatment Pharmacologic treatment Surgical treatment

Nonpharmacologic treatment EDUCATION (www.wemove.org) SUPPORT EXERCISE NUTRITION

Pharmacologic treatment NEUROPROTECTIVE THERAPY SYMPTOMATIC THERAPY

NEUROPROTECTIVE THERAPY All of the available treatments are symptomatic and do not appear to slow or reverse the natural course of the disease. Neuroprotective therapy of PD is still theoretical. Neuroprotective drug could be used in patients with early clinical signs of disease or potentially even prior to the appearance of disease in those shown to be at genetic risk. Selegiline and rasagiline (both monoamine oxidase inhibitors), dopamine agonists, and the complex I mitochondrial fortifier coenzyme Q10 have been evaluated in clinical trials and are receiving the most attention as possible neuroprotective agents

SYMPTOMATIC THERAPY Levodopa MAO B inhibitors Dopamine agonists COMT inhibitors Anticholinergic agents Amantadine

Drug Treatments of PD

Surgical treatment DEEP BRAIN STIMULATION THALAMOTOMY (With conventional thalamotomy, stereotactic surgical techniques are employed to create a lesion in the ventral intermediate (VIM) nucleus of the thalamus under electrophysiologic guidance. Gamma knife thalamotomy uses radiation delivered to the intracranial target, but electrophysiologic guidance is not possible) PALLIDOTOMY IMPLANTATIONS AND INFUSIONS: 1. Tissue transplantation 2. GDNF infusion 3. Duodenal levodopa infusion

MainTreatment Levodopa is the most effective drug in the treatment of PD. Most patients develop abnormal involuntary movements (dyskinesias) and unpredictable fluctuations in motor functioning within three years of treatment. Patients with onset before age 20 years are most likely to be affected. As a result, therapy is initiated with other drugs that will control the symptoms and delay the need for levodopa. They include anticholinergic drugs (eg, trihexyphenidyl, amantadine) and dopamine agonists (eg, pramipexole, ropinirole, and pergolide)

THE END